SPRO
LRMR

THOMAS FRANK E

Known title: DirectorCIK: 0001242616

THOMAS FRANK E's purchase track record

THOMAS FRANK E has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.

PurchaseStockAmount3 months6 months
2/27/2026LRMR$25K-34.5%-24.7%
2/14/2024LRMR$22K-34.2%-36.7%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 29, 2026

SPRO among stocks that gapped in Tuesday's session. Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.

this person other insiders at SPRO

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 30, 2026

Larimar Therapeutics Names John Harlow as President and COO. Larimar Therapeutics has appointed John Harlow as its new President and Chief Operating Officer, effective September 29. This leadership change is intended to strengthen the company's executive team. The stock is currently trading near its 52-week low, which provides context for this operational update.

this person other insiders at LRMR

Transaction History

SPRO▲ Buy$0
LRMR▲ Buy$25K
SPRO▲ Buy$0
SPRO▲ Buy$0
LRMR▲ Buy$22K
SPRO▲ Buy$0
SPRO▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.